Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

Clinica delle Malattie del Sistema Nervoso, Università di Torino, Italy.
Neurology (Impact Factor: 8.3). 03/1994; 44(3 Pt 1):406-13. DOI: 10.1212/WNL.44.3_Part_1.406
Source: PubMed

ABSTRACT We report a randomized, double-blind, placebo-controlled pilot trial of systemic high-dose recombinant interferon alfa-2a (rIFNA) in 20 patients with relapsing-remitting (RR) multiple sclerosis (MS). Patients received 9 million IU rIFNA (n = 12) or placebo (n = 8) intramuscularly every other day for 6 months. Clinical exacerbations or new or enlarging lesions on serial MRI occurred in two of 12 rIFNA-treated and in seven of eight placebo-treated patients (p < 0.005). There was only one enlarging MRI lesion in the rIFNA group, whereas 27 new or enlarging lesions were present in the placebo group (p < 0.01). Baseline lymphocyte interferon gamma production of 19.10 +/- 7.12 IU/ml significantly decreased to 3.03 +/- 0.66 IU/ml (p < 0.04) in the rIFNA group, whereas production was unchanged in the placebo group. The rIFNA was tolerated without dropouts or serious side effects, but fever, malaise, fatigue (interfering with daily activities in two patients), and leukopenia occurred frequently. Neuropsychological tests excluded neurotoxicity. High-dose systemic rIFNA might reduce clinical and MRI signs of disease activity in RR MS and should be investigated in larger trials.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Seventeen chronic progressive multiple sclerosis patients were treated with natural interferon-beta (IFN-β) for 2 years, thereafter they were followed up for 2 years. IFN-β was given 1 million IU/day i.m. for 1 week, then 3 million IU daily for 3 weeks followed by a maintenance regimen of 2 million IU twice a week for 23 months. Kurtzke Expanded Disability Status Scale score was 5.5 at entry and did not change at the end of the first year. It increased to 5.8 at the end of the second year and to 6.5 at the end of the follow-up. Three patients worsened after 1 year, six after 2 years and nine at the end of the follow-up. Brain MRI was performed at entry and after 1 year: mean lesion score increased by 13.4%. MRI changes were not correlated with clinical course. Natural IFN-β seemed to have some beneficial effect when high doses were given: this effect tended to disappear after IFN-β was reduced, followed by a more severe disease progression after its withdrawal.
    European Journal of Neurology 04/1995; 2(2):139-141. · 3.85 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Interferons (IFNs) are implicated as an important component of the innate immune system influencing viral infections, inflammation, and immune surveillance. We review here the complex biological activity of IFNs in the central nervous system (CNS) and associated glial–immune interactions, with focus specifically on the Type I IFNs in physiological and pathological conditions. IFN-α and IFN-β are the predominant Type I IFNs in the CNS. They are produced in the CNS by glial cells, mostly microglia and astrocytes, as well as by neurons. A variety of mechanisms stimulate IFN production in glial cells, including innate stimuli from Toll-like and other receptors, which can recognize endogenous entities, as well as pathogens. We will review evidence that differential signaling by IFN-α versus IFN-β through the common heterodimeric receptor IFNAR is the basis for CNS-selective Type I IFN response, and the capacity of CNS glial cells to produce and respond to Type I IFN. Differential signaling outcomes of IFN-α and IFN-β, which have been ascribed to differential affinity for IFNAR1 and IFNAR2, determine whether Type I IFN exert pathogenic or protective roles in the CNS. These points will be discussed with reference to selected neurological diseases, and effects of Type I IFN on the integrity of the blood–brain barrier.
    Glia 03/2014; 62(3):339-55. · 5.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Type I interferons (IFNs) are important in innate and adaptive immunity. They are used to treat virus infections, cancer, and multiple sclerosis (MS). There are 5 type I IFN families in humans-IFN-α with 13 subtypes, plus IFN-β, ɛ, κ, and ω. Because their receptor binding affinities vary, these IFNs have different gene induction profiles and quite variable therapeutic effects. IFN-α subtypes may each be specific for certain viruses, but can be neurotoxic. IFN-β induces IFN-α, plus has additional direct effects on target cells. IFN-β was the first therapy approved that could change the course of MS. It has broader specificity than IFN-α, enhances cognition in MS, and may be neuroprotective and can potentially enhance fertility in women. Priming the IFN signaling system with an injection of IFN-β can enhance subnormal type I IFN signals in MS. Many other commonly used drugs and vitamins may potentiate clinical benefits of IFN-β.
    Journal of Interferon & Cytokine Research 08/2014; 34(8):589-99. · 3.90 Impact Factor